Australian medicinal cannabis revenue is tipped to double this year amid growing confidence in the emerging sector. And WA is poised to maintain a significant hold of the market share. While the State is recognised globally for its optimal growing conditions, local cultivators, manufacturers and researchers have also benefited from limited COVID-19 interference in their operations. Read the full story…

180 Markets is turning the ASX around to make it fairer and easier for you to access capital raises. Our goal is to give investors the same access to capital raises as the world’s biggest fund managers. No more advantaged information or being the last person in. But it gets even better. You have true ownership of your shares, you…

By Caitlyn Rintoul & Charlotte Elton Perth family describes their desperation when they sought cannabis for autistic, suicidal son. – The West Australian

It may come as a surprise to many that the average medicinal cannabis user in Australia is a woman aged in her 50s. She may be taking the prescription medication to relieve pain or help her sleep. She may be a cancer patient. Yet while it has been legal for her to use medical cannabis in Australia since 2016, she…

Australia’s fledgling medicinal cannabis sector has been blazing ahead with research projects in the face of the COVID-19 pandemic and well-known investors are looking for winners. Investor buzz around cannabis stocks with new treatments

Zelira Therapeutics (ZLD) proprietary cannabinoid medicine, Zenivol, can now be prescribed to patients in Australia. This comes after the company received the Therapeutic Goods Administration’s (TGA) Special Access Scheme approval for the treatment. Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia

Shares in Perth-based Zelira Therapeutics have surged after the medicinal cannabis company announced its insomnia treatment can now be prescribed in Australia. The company’s stock was up 11.7 per cent to 6.7¢ at 12.50pm Zelira Therapeutics’ insomnia treatment gets TGA tick

As a massive class action builds over concussion in the AFL, another problem is emerging. Heavy knocks are causing injuries that leave players suffering from a lifetime of crippling chronic pain. Medicinal cannabis trial could help retired AFL players manage chronic pain

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has formed an oral care products subsidiary to commercialise scientifically formulated, hemp-derived cannabinoid-based oral care products in the USA. The first oral care product will be a cannabinoid-containing proprietary toothpaste formulation developed by Sprinjene CEO and founder Dr Sayed Ibrahim. Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has expanded its network in the US by launching its HOPE range of products for autism sufferers in Louisiana, USA, where laws have recently been expanded to allow more patients access to medical marijuana. With the passage of ACT No 286, all physicians in the State are now allowed to recommend medical marijuana to any…

  • 1
  • 2
  • 7

Start typing and press Enter to search

Shopping Cart